Novartis bolsters its immuno-oncology pipeline with Xencor’s bispecific antibodies
By Natasha Berry
Pharma Deals Review: Vol 2016 Issue 7 (Table of Contents)
Published: 9 Jul-2016
DOI: 10.3833/pdr.v2016.i7.2173 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Novartis has entered into a collaboration and license agreement with California-based Xencor in a deal worth US$2...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS